Literature DB >> 15640759

Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo.

Isabel Lastres-Becker1, Nicolas Bizat, Frédéric Boyer, Philippe Hantraye, Javier Fernández-Ruiz, Emmanuel Brouillet.   

Abstract

Several neurotransmitter systems are involved in the pathogenesis of Huntington's disease. Here, we examined the involvement of cannabinoid CB(1) receptors in striatal degeneration in the rat model of this disease generated by administration of 3-nitropropionic acid (3NP). Several days before onset of striatal degeneration, G-protein activation by cannabinoid agonists was significantly decreased whereas density and mRNA levels of CB(1) receptors remained essentially normal. This change was transient, CB(1) receptors recovering full functionality after few days. Later, at onset of striatal degeneration, profound alterations of CB(1) receptors were detected, including marked reductions of their density, mRNA levels and coupling to G proteins. In these rats, the administration of the cannabinoid agonist Delta(9)-tetrahydrocannabinol was neuroprotective, which indicates that the early loss of CB(1) receptor signaling could be instrumental in 3NP toxicity. In conclusion, the present study supports the hypothesis that cannabinoid receptors, possibly the CB(1) receptor subtype, may be involved in HD pathogenesis and could be an interesting therapeutic target to slow disease progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15640759     DOI: 10.1097/00001756-200410250-00015

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  16 in total

Review 1.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 2.  Cannabinoids and neuroprotection in basal ganglia disorders.

Authors:  Onintza Sagredo; Moisés García-Arencibia; Eva de Lago; Simone Finetti; Alessandra Decio; Javier Fernández-Ruiz
Journal:  Mol Neurobiol       Date:  2007-06-23       Impact factor: 5.590

Review 3.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Authors:  Sara Valdeolivas; Carmen Navarrete; Irene Cantarero; María L Bellido; Eduardo Muñoz; Onintza Sagredo
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

5.  A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

Authors:  Jose Luis López-Sendón Moreno; Juan García Caldentey; Patricia Trigo Cubillo; Carolina Ruiz Romero; Guillermo García Ribas; M A Alonso Alonso Arias; María Jesús García de Yébenes; Rosa María Tolón; Ismael Galve-Roperh; Onintza Sagredo; Sara Valdeolivas; Eva Resel; Silvia Ortega-Gutierrez; María Laura García-Bermejo; Javier Fernández Ruiz; Manuel Guzmán; Justo García de Yébenes Prous
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

6.  Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors.

Authors:  Marisol Maya-López; Ana Laura Colín-González; Gabriela Aguilera; María Eduarda de Lima; Ana Colpo-Ceolin; Edgar Rangel-López; Juana Villeda-Hernández; Daniel Rembao-Bojórquez; Isaac Túnez; Armando Luna-López; Roberto Lazzarini-Lechuga; Viridiana Yazmín González-Puertos; Pedro Posadas-Rodríguez; Alejandro Silva-Palacios; Mina Königsberg; Abel Santamaría
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

Review 7.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 8.  The endocannabinoid system as a target for the treatment of motor dysfunction.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

9.  Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Authors:  Sara Valdeolivas; Valentina Satta; Roger G Pertwee; Javier Fernández-Ruiz; Onintza Sagredo
Journal:  ACS Chem Neurosci       Date:  2012-02-09       Impact factor: 4.418

10.  Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Authors:  Onintza Sagredo; Sara González; Ilia Aroyo; María Ruth Pazos; Cristina Benito; Isabel Lastres-Becker; Juan P Romero; Rosa M Tolón; Raphael Mechoulam; Emmanuel Brouillet; Julián Romero; Javier Fernández-Ruiz
Journal:  Glia       Date:  2009-08-15       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.